300765 Stock Overview
Engages in the research and development, production, and sales of biopharmaceuticals, APIs, and functional foods in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
CSPC Innovation Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.74 |
| 52 Week High | CN¥40.62 |
| 52 Week Low | CN¥19.69 |
| Beta | -0.14 |
| 11 Month Change | -9.41% |
| 3 Month Change | 11.72% |
| 1 Year Change | -7.48% |
| 33 Year Change | 344.17% |
| 5 Year Change | 388.87% |
| Change since IPO | 364.18% |
Recent News & Updates
Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?
Nov 21
Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems
Oct 31Recent updates
Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?
Nov 21Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems
Oct 31Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%
Sep 30Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)
Aug 16CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk
Jul 04CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture
Apr 29CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32
Apr 25CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable
Apr 24Shareholder Returns
| 300765 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 4.8% | -1.3% | -3.4% |
| 1Y | -7.5% | -3.4% | 6.1% |
Return vs Industry: 300765 underperformed the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 300765 underperformed the CN Market which returned 6.1% over the past year.
Price Volatility
| 300765 volatility | |
|---|---|
| 300765 Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 300765 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300765's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1,887 | Feng Han | www.xnwpharma.net |
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, APIs, and functional foods in China and internationally. It offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dihydroxyphylline, theobromine, pentoxifylline, doxofylline, and raw enzymes; and health food products, such as Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, etc. The company was founded in 2006 and is headquartered in Shijiazhuang, China. CSPC Innovation Pharmaceutical Co., Ltd.
CSPC Innovation Pharmaceutical Co., Ltd. Fundamentals Summary
| 300765 fundamental statistics | |
|---|---|
| Market cap | CN¥39.69b |
| Earnings (TTM) | CN¥513.13m |
| Revenue (TTM) | CN¥2.04b |
75.3x
P/E Ratio18.9x
P/S RatioIs 300765 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300765 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.04b |
| Cost of Revenue | CN¥1.20b |
| Gross Profit | CN¥844.52m |
| Other Expenses | CN¥331.39m |
| Earnings | CN¥513.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.37 |
| Gross Margin | 41.33% |
| Net Profit Margin | 25.11% |
| Debt/Equity Ratio | 0% |
How did 300765 perform over the long term?
See historical performance and comparison